Biocon Biologics a subsidiary of Biocon and its partner Viatris Inc. has confirmed that Prime Therapeutics, a leading pharmacy benefit manager (PBM) in the US, serving nearly 33 million members, will list Semglee (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) Injection, an unbranded product, as preferred insulin over the Lantus brand on its national formularies. Broad coverage of the products, starting January 1, 2022, will help ensure that millions of patients in the Prime Therapeutics network who need insulin receive the full benefits of and access to high-quality treatment with lower or consistent out-of-pocket costs. Interchangeability allows for substitution for the reference product at the pharmacy counter.

The decision by Prime Therapeutics follows the U.S. Food and Drug Administration's (FDA) approval of the first-ever interchangeable biosimilar through the interchangeable pathway. Biocon Biologics' partner Viatris will introduce the two (branded and unbranded) products, both of which will be available in pen and vial presentations and are interchangeable for the reference brand, Lantus. Biocon Biologics and Viatris co-developed the products, and together the companies are committed to improving patients' access to sustainable, high-quality and affordable healthcare.

Semglee (insulin glargine-yfgn) injection and Insulin Glargine (insulin glargine-yfgn) Injection will be available before the end of the year, and further details related to Viatris' access programs, which aim to ensure that as many patients as possible will benefit from the product, will be available at that time.